阿帕替尼治疗晚期肝癌的研究进展

Research Progress of Apatinib in the Treatment of Advanced Liver Cancer

随着对肝癌发病机制研究的不断推进,晚期肝癌的治疗已经是化疗联合靶向药物,免疫联合药物的综合治疗时代。阿帕替尼是一种新型口服小分子酪氨酸激酶抑制剂,已被用于晚期肝癌的临床治疗中,并显示出较好的抗肿瘤效应及较低的不良反应,目前,阿帕替尼在恶性肿瘤抗血管生成靶向治疗的应用价值越来越高,未来将为晚期肝癌的治疗提供新的思路。

With the continuous advancement of the research on the pathogenesis of liver cancer, the treatment of advanced liver cancer has become a comprehensive era of chemotherapy combined with targeted drugs and immunotherapy combined with drugs. Path for he is a new kind of oral small molecule tyrosine kinase inhibitor, has been used in clinical treatment of advanced liver cancer, and showed good antitumor effect and lower adverse reactions, at present, the path for Nepal in targeted therapy of malignant tumor anti-angiogenesis application value is higher and higher, the future will provide new train of thought for the treatment of advanced liver cancer.